Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes

Mohammad Amin Honardoost,Andreas Adinatha,Florian Schmidt,Bobby Ranjan,Maryam Ghaeidamini,Nirmala Arul Rayan,Michelle Gek Liang Lim,Ignasius Joanito,Quy Xiao Xuan Lin,Deepa Rajagopalan,Shi Qi Mok,You Yi Hwang,Anis Larbi,Chiea Chuen Khor,Roger Foo,Bernhard Otto Boehm,Shyam Prabhakar

DOI: https://doi.org/10.1186/s13073-024-01300-z

IF: 15.266

2024-03-30

Genome Medicine

Abstract:Type 1 diabetes mellitus (T1DM) is a prototypic endocrine autoimmune disease resulting from an immune-mediated destruction of pancreatic insulin-secreting  cells. A comprehensive immune cell phenotype evaluation in T1DM has not been performed thus far at the single-cell level.

genetics & heredity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the systemic abnormalities of immune cells in type 1 diabetes mellitus (T1DM) and the definition of their molecular subtypes. Specifically, the authors conducted a comprehensive immunocyte phenotyping analysis of peripheral blood mononuclear cells (PBMCs) from 46 diagnosed type 1 diabetes patients (T1DM, stage 3) and 31 matched healthy control groups through single - cell RNA sequencing (scRNA - seq) technology. The main objectives of the study include:

1. **Revealing immune cell abnormalities in type 1 diabetes**: Through high - resolution single - cell transcriptome data, detect the differences in immune cell types and gene expression between T1DM patients and healthy control groups, especially explore whether these differences reflect systemic immune dysregulation.

2. **Defining disease - related molecular subtypes**: Construct the T1DM metagene Z - score (TMZ score) based on single - cell data to distinguish cases from controls and further classify patients into different molecular subtypes.

3. **Exploring the potential for non - invasive test development**: The research results may contribute to the development of new non - invasive diagnostic tools for early identification and patient stratification, thereby guiding personalized treatment.

### Main findings

- **Widespread immune cell abnormalities**: The study found that there are significant gene expression changes in the circulating immune cells of T1DM patients, involving 1,784 dysregulated genes in 13 immune cell types. These changes not only quantitatively exceed those in systemic autoimmune diseases such as systemic lupus erythematosus (SLE), but also involve multiple important signaling pathways, such as Wnt signaling, interferon signaling, T/NK cell migration, B - cell antigen presentation, and monocyte activation.

- **Definition of molecular subtypes**: By constructing the T1DM metagene Z - score (TMZ score), researchers were able to distinguish cases from controls and divide patients into different molecular subtypes. This score is related to known T1DM prognostic immune markers and drug responses in clinical trials.

- **Potential clinical applications**: The research results revealed the abnormal systemic immune cell network in T1DM, defined disease - related molecular subtypes, and have the potential for developing non - invasive tests and patient stratification.

### Conclusion

This study revealed unexpectedly strong systemic immune cell dysregulation in type 1 diabetes, defined disease - related molecular subtypes, and has the potential for developing non - invasive tests and patient stratification. These findings provide important clues for further understanding the pathological mechanisms of T1DM and developing more effective treatment methods.